Effects of Scheduled Exercise on Cancer-Related Fatigue in Women with Early Breast Cancer
Table 1
Demographics and characteristics of study population ().
Variable
Total sample ()
Intervention group ()
Control group ()
value
(%)
(%)
(%)
Age (years)
0.576
Mean SD
52.2 9.3
50.8 9.7
53.6 8.8
Body weight (kg)
0.178
Mean SD
70.5 13.8
69.0 11.6
72.0 15.7
Waist line (cm)
0.444
Mean SD
83.1 11.1
81.6 9.9
84.5 12.0
Living conditions
Living alone
10 (14.9)
5 (15.2)
5 (14.7)
0.510
Living with partner
54 (80.6)
27 (81.8)
27 (79.4)
0.204
Living with others
2 (3.0)
0 (0)
2 (5.9)
0.086
Missing
1 (1.5)
1 (3.0)
0 (0)
Ethnicity
0.638
Norwegian
57 (85.1)
27 (81.8)
30 (88.2)
Other
9 (13.4)
5 (15.6)
4 (11.8)
Missing
1 (1.5)
1 (3.0)
0 (0)
Children living at home
0.205
Yes
29 (43.3)
17 (53.1)
12 (35.3)
No
37 (55.2)
15 (46.9)
22 (65.7)
Missing
1 (1.5)
3.0 (1)
0 (0)
Education
0.186
High school
12 (17.9)
4 (12.5)
8 (23.5)
College
23 (34.3)
9 (28.2)
14 (41.1)
University
31 (46.3)
19 (59.3)
12 (35.2)
Missing
1 (1.5)
1 (3.0)
0.0 (0)
Currently employed
0.331
Yes
19 (28.4)
12 (40.0)
7 (21.2)
Yes, part time
14 (20.9)
5 (16.7)
9 (27.3)
No
30 (44.8)
13 (43.3)
17 (51.5)
Missing
4 (6.0)
3 (9.03)
1 (2.9)
Cancer stagea
0.394
I
19 (31.7)
7 (24.2)
12 (38.7)
II
34 (56.7)
19 (65.5)
15 (48.4)
III
7 (11.6)
3 (10.3)
4 (12.9)
PgR status
0.782
Negative
32 (47.8)
16 (48.5)
16 (47.1)
Positive
35 (52.2)
17 (51.5)
18 (52.9)
ER status
0.464
Negative
21 (31.3)
13 (39.4)
8 (23.5)
Positive
46 (68.7)
20 (60.6)
26 (76.5)
HER-2 status
0.254
Negative
55 (82.0)
26 (78.8)
29 (85.3)
Positive
11 (16.4)
7 (21.2)
4 (11.8)
Missing
1 (1.5)
0.0 (0)
1 (2.9)
Surgery
0.866
Lumpectomy
22 (32.8)
21 (63.6)
24 (70.6)
Mastectomy
45 (67.2)
12 (36.4)
10 (29.4)
Chemotherapy regimen
0.898
FEC-60
33 (49.3)
16 (48.5)
17 (50.0)
FEC-100
4 (6.0)
2 (6.1)
2 (5.9)
FEC-60 + Taxotere
18 (26.9)
8 (24.2)
10 (29.4)
FEC-100 + Taxotere
5 (7.5)
3 (9.1)
2 (5.9)
FEC-60 + Taxol
7 (10.4)
4 (12.1)
3 (8.8)
Other adjuvant systemic treatment
56 (93.3)
27 (93.1)
29 (93.5)
0.612
Radiotherapy
48 (71.7)
22 (75.9)
26 (83.9)
Intervention duration (weeks)
0.807
Mean SD
17.2 7.7
16.7 7.6
17.6 7.9
SD: standard deviation, ER: estrogen receptor, PgR: progesterone receptor, FEC-60: chemotherapy regimen of fluorouracil, epirubicin and cyclophosphamide administered in 60 mg/m2 dosage. FEC-100: chemotherapy regimen of fluorouracil, epirubicin and cyclophosphamide administered in 100 mg/m2 dosage, HER-2: human epidermal growth factor receptor 2.
aCancer stage based on pTNM staging system.
